MYSTIC was excluded because durvalumab is not indicated as monotherapy in advanced NSCLC, given MYSTIC failed to meet its primary endpoint.56 IMpower110 was only included in the sensitivity analyses because an incompatible PD-L1 assay (SP142) was used for patient selection. The gene discussed is CD274; the disease is non-small cell lung carcinoma.